These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
240 related articles for article (PubMed ID: 35783677)
1. Lipid nanoparticles in the development of mRNA vaccines for COVID-19. Wilson B; Geetha KM J Drug Deliv Sci Technol; 2022 Aug; 74():103553. PubMed ID: 35783677 [TBL] [Abstract][Full Text] [Related]
2. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines. Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336 [TBL] [Abstract][Full Text] [Related]
3. Role of nanotechnology behind the success of mRNA vaccines for COVID-19. Khurana A; Allawadhi P; Khurana I; Allwadhi S; Weiskirchen R; Banothu AK; Chhabra D; Joshi K; Bharani KK Nano Today; 2021 Jun; 38():101142. PubMed ID: 33815564 [TBL] [Abstract][Full Text] [Related]
5. Effect of Pfizer/BioNTech and Oxford/AstraZeneca vaccines against COVID-19 morbidity and mortality in real-world settings at countrywide vaccination campaign in Saudi Arabia. Meo SA; Fahad Al-Jassir F; Al-Qahtani S; Albarrak R; Usmani AM; Klonoff DC Eur Rev Med Pharmacol Sci; 2021 Nov; 25(22):7185-7191. PubMed ID: 34859883 [TBL] [Abstract][Full Text] [Related]
6. BNT162b2 mRNA COVID-19 Vaccine: First Approval. Lamb YN Drugs; 2021 Mar; 81(4):495-501. PubMed ID: 33683637 [TBL] [Abstract][Full Text] [Related]
7. SARS-CoV-2: Unique Challenges of the Virus and Vaccines. Mahmoodpoor A; Sanaie S; Samadi P; Yousefi M; Nader ND Immunol Invest; 2021 Oct; 50(7):802-809. PubMed ID: 34109900 [TBL] [Abstract][Full Text] [Related]
8. Editorial: First Full Regulatory Approval of a COVID-19 Vaccine, the BNT162b2 Pfizer-BioNTech Vaccine, and the Real-World Implications for Public Health Policy. Parums DV Med Sci Monit; 2021 Sep; 27():e934625. PubMed ID: 34483336 [TBL] [Abstract][Full Text] [Related]
9. From influenza to COVID-19: Lipid nanoparticle mRNA vaccines at the frontiers of infectious diseases. Pilkington EH; Suys EJA; Trevaskis NL; Wheatley AK; Zukancic D; Algarni A; Al-Wassiti H; Davis TP; Pouton CW; Kent SJ; Truong NP Acta Biomater; 2021 Sep; 131():16-40. PubMed ID: 34153512 [TBL] [Abstract][Full Text] [Related]
10. Are the Allergic Reactions of COVID-19 Vaccines Caused by mRNA Constructs or Nanocarriers? Immunological Insights. Selvaraj G; Kaliamurthi S; Peslherbe GH; Wei DQ Interdiscip Sci; 2021 Jun; 13(2):344-347. PubMed ID: 34021862 [TBL] [Abstract][Full Text] [Related]
12. Difference in the lipid nanoparticle technology employed in three approved siRNA (Patisiran) and mRNA (COVID-19 vaccine) drugs. Suzuki Y; Ishihara H Drug Metab Pharmacokinet; 2021 Dec; 41():100424. PubMed ID: 34757287 [TBL] [Abstract][Full Text] [Related]
13. Can mRNA Vaccines Turn the Tables During the COVID-19 Pandemic? Current Status and Challenges. Sagili Anthony DP; Sivakumar K; Venugopal P; Sriram DK; George M Clin Drug Investig; 2021 Jun; 41(6):499-509. PubMed ID: 33754328 [TBL] [Abstract][Full Text] [Related]
14. Developing Biodegradable Lipid Nanoparticles for Intracellular mRNA Delivery and Genome Editing. Qiu M; Li Y; Bloomer H; Xu Q Acc Chem Res; 2021 Nov; 54(21):4001-4011. PubMed ID: 34668716 [TBL] [Abstract][Full Text] [Related]
15. The Advisory Committee on Immunization Practices' Recommendation for Use of Moderna COVID-19 Vaccine in Adults Aged ≥18 Years and Considerations for Extended Intervals for Administration of Primary Series Doses of mRNA COVID-19 Vaccines - United States, February 2022. Wallace M; Moulia D; Blain AE; Ricketts EK; Minhaj FS; Link-Gelles R; Curran KG; Hadler SC; Asif A; Godfrey M; Hall E; Fiore A; Meyer S; Su JR; Weintraub E; Oster ME; Shimabukuro TT; Campos-Outcalt D; Morgan RL; Bell BP; Brooks O; Talbot HK; Lee GM; Daley MF; Oliver SE MMWR Morb Mortal Wkly Rep; 2022 Mar; 71(11):416-421. PubMed ID: 35298454 [TBL] [Abstract][Full Text] [Related]
16. Interim Recommendations of the Advisory Committee on Immunization Practices for Use of Moderna and Pfizer-BioNTech COVID-19 Vaccines in Children Aged 6 Months-5 Years - United States, June 2022. Fleming-Dutra KE; Wallace M; Moulia DL; Twentyman E; Roper LE; Hall E; Link-Gelles R; Godfrey M; Woodworth KR; Anderson TC; Rubis AB; Shanley E; Jones JM; Morgan RL; Brooks O; Talbot HK; Lee GM; Bell BP; Daley M; Meyer S; Oliver SE MMWR Morb Mortal Wkly Rep; 2022 Jul; 71(26):859-868. PubMed ID: 35771731 [TBL] [Abstract][Full Text] [Related]
17. Tozinameran (BNT162b2) Vaccine: The Journey from Preclinical Research to Clinical Trials and Authorization. Khehra N; Padda I; Jaferi U; Atwal H; Narain S; Parmar MS AAPS PharmSciTech; 2021 Jun; 22(5):172. PubMed ID: 34100150 [TBL] [Abstract][Full Text] [Related]
18. FDA-authorized mRNA COVID-19 vaccines are effective per real-world evidence synthesized across a multi-state health system. Pawlowski C; Lenehan P; Puranik A; Agarwal V; Venkatakrishnan AJ; Niesen MJM; O'Horo JC; Virk A; Swift MD; Badley AD; Halamka J; Soundararajan V Med; 2021 Aug; 2(8):979-992.e8. PubMed ID: 34223401 [TBL] [Abstract][Full Text] [Related]